<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Gouveia Brazao, C.A. de</title>
    <link>http://repub.eur.nl/res/aut/6007/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors (Article)</title>
      <link>http://repub.eur.nl/res/pub/10129/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>Human germ cell tumors (GCTs) may have variable histology and clinical
      behavior, depending on factors such as sex of the patient, age at clinical
      diagnosis, and anatomical site of the tumor. Some types of GCT, i.e., the
      seminomas/germinomas/dysgerminomas and embryonal carcinomas (the stem cell
      component of nonseminomas), have pluripotent potential, which is
      demonstrated by their capacity to differentiate into somatic and/or
      extraembryonic elements. Although embryonal carcinoma cells are
      intrinsically pluripotent, seminoma/germinoma/dysgerminoma cells, as well
      as their precursor carcinoma in situ/gonadoblastoma cells, have the
      phenotype of early germ cells that can be activated to pluripotency. The
      other types of GCT (teratomas and yolk sac tumors of infants and newborn,
      dermoid cyst of the ovary, and spermatocytic seminoma of elderly) are
      composed of (fully) differentiated tissues and lack the appearance of
      undifferentiated and pluripotent stem cells. OCT3/4, a transcription
      factor also known as OTF3 and POU5F1, is involved in regulation of
      pluripotency during normal development and is detectable in embryonic stem
      and germ cells. We analyzed the presence of POU5F1 in GCT and other tumor
      types using immunohistochemistry. The protein was consistently detected in
      carcinoma in situ/gonadoblastoma, seminomas/germinoma/dysgerminoma, and
      embryonal carcinoma but not in the various types of differentiated
      nonseminomas. Multitumor tissue microarray analysis covering &gt;100
      different tumor categories and 3600 individual cancers verified that
      POU5F1 expression is specific for particular subtypes of GCT of adults. No
      protein was observed in GCT of newborn and infants, spermatocytic
      seminomas, and the various tumors of nongerm cell origin. In addition, no
      difference in staining pattern was found in chemosensitive and
      chemoresistant GCT of adults. These results indicate preservation of the
      link between POU5F1 and pluripotency, as reported during normal
      development, after malignant transformation. Therefore, POU5F1
      immunohistochemistry is an informative diagnostic tool for pluripotent GCT
      and offers new insights into the histological heterogeneity of this
      cancer.</description>
    </item> <item>
      <title>Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors (Article)</title>
      <link>http://repub.eur.nl/res/pub/10242/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>Testicular germ-cell tumors (TGCTs) of adolescents and adults originate
      from intratubular germ cell neoplasia (ITGCN), which is composed of the
      malignant counterparts of embryonal germ cells. ITGCN cells are
      characterized, among others, by the presence of stem cell factor receptor
      c-KIT. Once established, ITGCN will always progress to invasiveness.
      Approximately 2.5-5% of patients with a TGCT will develop bilateral
      disease and require complete castration, resulting in infertility, a need
      for lifelong androgen replacement, and psychological stress. To date, the
      only way to predict a contralateral tumor is surgical biopsy of the
      contralateral testis to demonstrate ITGCN. We did a retrospective study of
      224 unilateral and 61 proven bilateral TGCTs (from 46 patients, in three
      independently collected series in Europe) for the presence of activating
      c-KIT codon 816 mutations. A c-KIT codon 816 mutation was found in three
      unilateral TGCT (1.3%), and in 57 bilateral TGCTs (93%; P &lt; 0.0001). In
      the two wild-type bilateral tumors for which ITGCN was available, the
      preinvasive cells contained the mutation. The mutations were somatic in
      origin and identical in both tumors. We conclude that somatic activating
      codon 816 c-KIT mutations are associated with development of bilateral
      TGCT. Detection of c-KIT codon 816 mutations in unilateral TGCT identifies
      patients at risk for bilateral disease. These patients may undergo
      tailored treatment to prevent the development of bilateral disease, with
      retention of testicular hormonal function.</description>
    </item>
  </channel>
</rss>